Abstract
Nivolumab is a standard treatment option in several advanced malignancies, but safety and efficacy are still unknown in patients with human immunodeficiency virus (HIV) infection. We describe a case series of people living with HIV (PLWH) receiving nivolumab in the Veterans Health Administration (VA) and report responses and toxicities. We identified all PLWH who received nivolumab at any VA facility since 2000 in the Corporate Data Warehouse (CDW), which provides nationwide research access to VA electronic medical records. We identified 16 HIV-infected nivolumab recipients. The median number of nivolumab doses received was 6 (range, 1-32). Changes in CD4 count during therapy were variable, with 70% (7/10) of patients experiencing increases. Half of PLWH were treated for non-small-cell lung cancer; 2 for Hodgkin lymphoma (HL), 2 for renal cell carcinoma, and 4 for off-label cancers. For non-small-cell lung cancer, 7 patients had evaluable responses. Although 5 of 7 patients immediately progressed, 1 had a partial response and 1 had stable disease, which were both durable. Two of 16 (14%) PLWH had complete responses; both with HL (2/2 HL, 100%). The prevalence of immune-related adverse effects was 40% overall (6/15); 27% (4/15) ...Continue Reading
References
Feb 1, 1992·The Journal of Clinical Investigation·A ShiraiD M Klinman
Sep 5, 1986·Science·S M SchnittmanA S Fauci
Aug 25, 1983·The New England Journal of Medicine·H C LaneA S Fauci
Jan 1, 1994·Autoimmunity·J A SavigeS M Crowe
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·S MoirA S Fauci
Nov 8, 2003·Blood·Angelo De MilitoFrancesca Chiodi
Apr 30, 2005·Science·Barton F HaynesS Munir Alam
May 19, 2005·Immunology Letters·Dorothea StahlUNKNOWN ANRS SEROCO study group
Aug 19, 2006·Nature Medicine·Lydie TrautmannRafick-Pierre Sekaly
Aug 22, 2006·Nature·Cheryl L DayBruce D Walker
Aug 19, 2011·The Journal of Infectious Diseases·Aristotelis TsiakalosNikolaos V Sipsas
Jul 22, 2014·Lancet·Colette J SmithJens D Lundgren
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Aug 16, 2016·PloS One·Adam TrickeyUNKNOWN Antiretroviral Therapy Cohort Collaboration (ART-CC)
Feb 23, 2017·The Lancet Oncology·Van K MorrisCathy Eng
Mar 30, 2017·AIDS·Gwenaëlle Le GarffAmélie Guihot
Jun 24, 2017·Journal for Immunotherapy of Cancer·Jose D Sandoval-SusMichael V Jagal
Nov 7, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M HentrichP Bojko
Nov 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M HentrichP Bojko
Citations
Oct 22, 2019·AIDS·Baptiste AbbarJean-Philippe Spano
Mar 12, 2020·JCO Oncology Practice·Ibrahim Halil SahinBassel F El-Rayes
Jan 29, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Renée M Van der SluisSharon R Lewin
Aug 23, 2020·Current HIV/AIDS Reports·Kathryn LurainThomas S Uldrick
Aug 6, 2020·International Journal of Molecular Sciences·Ayumi KuzumeYosuke Minami
Sep 27, 2019·Frontiers in Immunology·Camille E PuronenThomas S Uldrick
Jun 27, 2020·AIDS·Ilaria ProiettiConcetta Potenza
Feb 17, 2019·The Annals of Pharmacotherapy·Jacqueline L OlinLinda M Spooner
Jul 3, 2020·Blood·Blake J RustChristopher W Peterson
Sep 9, 2019·Trends in Molecular Medicine·Michael S AbersDimitrios P Kontoyiannis
Dec 11, 2020·The Cancer Journal·Mitchell S von ItzsteinDavid E Gerber
Dec 29, 2020·Journal for Immunotherapy of Cancer·Sattva S NeelapuMichael R Bishop
Mar 28, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K RzeniewiczS Turajlic
Apr 23, 2021·Infectious Agents and Cancer·Mengmeng ZhangYu Zhang
Jan 13, 2022·Future Oncology·Emre YekedüzYüksel Ürün